ABIVAX Société Anonyme (NASDAQ:ABVX – Get Free Report) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 853,600 shares, an increase of 47.9% from the December 15th total of 577,200 shares. Based on an average daily trading volume, of 162,900 shares, the short-interest ratio is currently 5.2 days. Approximately 1.6% of the company’s shares are sold short.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on the company. Citizens Jmp raised ABIVAX Société Anonyme to a “strong-buy” rating in a research note on Wednesday, December 4th. JMP Securities reiterated a “market outperform” rating and issued a $33.00 price objective on shares of ABIVAX Société Anonyme in a research report on Friday, January 10th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, ABIVAX Société Anonyme currently has an average rating of “Buy” and an average price target of $38.67.
Get Our Latest Stock Analysis on ABIVAX Société Anonyme
ABIVAX Société Anonyme Stock Performance
Institutional Trading of ABIVAX Société Anonyme
Several institutional investors and hedge funds have recently bought and sold shares of ABVX. abrdn plc lifted its position in ABIVAX Société Anonyme by 167.7% during the third quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after buying an additional 198,225 shares during the period. Point72 Asset Management L.P. lifted its stake in shares of ABIVAX Société Anonyme by 28.2% in the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after buying an additional 119,300 shares in the last quarter. Walleye Capital LLC boosted its stake in ABIVAX Société Anonyme by 45.8% during the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after purchasing an additional 80,807 shares during the last quarter. BNP Paribas Financial Markets boosted its position in shares of ABIVAX Société Anonyme by 82.6% during the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after buying an additional 5,900 shares during the last quarter. Finally, GAMMA Investing LLC bought a new stake in ABIVAX Société Anonyme in the 4th quarter worth about $29,000. 47.91% of the stock is currently owned by hedge funds and other institutional investors.
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Recommended Stories
- Five stocks we like better than ABIVAX Société Anonyme
- Ride Out The Recession With These Dividend Kings
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- With Risk Tolerance, One Size Does Not Fit All
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for ABIVAX Société Anonyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIVAX Société Anonyme and related companies with MarketBeat.com's FREE daily email newsletter.